title: Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms.
abstract: Replacement of antipsychotic drugs with quetiapine (QTP) was tried in a naturalistic setting in chronic schizophrenic patients who still showed moderate psychiatric symptoms and either showed extrapyramidal symptoms (EPS) or took anti-parkinson drugs for the EPS. QTP was added on and gradually increased while the previous drugs were tapered and discontinued whenever possible. Clinical symptoms, objective and subjective QOL, and EPS were measured before and 6 months after QTP addition, using Brief Psychiatric Rating Scale (BPRS), Quality of Life Scale (QLS), Schizophrenia Quality of Life Scale (SQLS) and Drug-Induced Extrapyramidal Symptom Scale (DIEPSS), respectively. Twenty-one patients completed the trial and received the assessment. It was found that replacement with QTP-improved clinical symptoms, objective and subjective QOL and EPS. This improvement was equally observed in not only patients who switched to QTP monotherapy (n = 11) but also patients who took QTP together with reduced small doses (4.4 +/- 4.3 mg/day) of previous drugs (n = 11). The results suggest that replacement with QTP improves symptoms as well as objective and subjective QOL in a subgroup of schizophrenia.
authors.affiliation: Department of Psychiatry, University of Tokushima School of Medicine, Tokushima city, Tokushima, Japan.
authors.forename: Takahide
authors.initials: T
authors.lastname: Taniguchi
authors.forename: Satsuki
authors.initials: S
authors.lastname: Sumitani
authors.forename: Michitaka
authors.initials: M
authors.lastname: Aono
authors.forename: Junichi
authors.initials: J
authors.lastname: Iga
authors.forename: Sawako
authors.initials: S
authors.lastname: Kinouchi
authors.forename: Hirosi
authors.initials: H
authors.lastname: Aki
authors.forename: Mami
authors.initials: M
authors.lastname: Matsushita
authors.forename: Kyoko
authors.initials: K
authors.lastname: Taniguchi
authors.forename: Mami
authors.initials: M
authors.lastname: Tsuno
authors.forename: Kazunari
authors.initials: K
authors.lastname: Yamanishi
authors.forename: Masahito
authors.initials: M
authors.lastname: Tomotake
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kaneda
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Ohmori
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D003987:Dibenzothiazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D000069348:Quetiapine Fumarate; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate